Age-Related Changes in Tumor Immune Cell Spatial Organization

Abstract

Ageing reshapes the tumor immune microenvironment through coordinated changes in immune-cell abundance, phenotype, function, tissue trafficking, extracellular matrix composition, vascular biology, and stromal architecture. These alterations influence where immune cells accumulate within tumors, whether they penetrate malignant regions, and how effectively they communicate with cancer cells and one another. Although older adults bear a substantial proportion of the global cancer burden, the spatial consequences of immunosenescence and inflammaging remain incompletely incorporated into clinical oncology. This review examines the epidemiology, mechanisms, clinical manifestations, diagnostic implications, therapeutic consequences, and emerging interventions associated with age-dependent tumor immune organization. Particular attention is given to the distinction between immune-excluded, immune-desert, and inflamed tumor patterns; age-related changes in T cells, myeloid cells, natural killer cells, regulatory populations, fibroblasts, vasculature, and lymphatic structures; and the implications for immune checkpoint blockade, cellular therapy, vaccination, and combination treatment. Spatially resolved technologies, including multiplex imaging, imaging mass cytometry, spatial transcriptomics, and artificial intelligence-assisted pathology, are increasingly capable of defining these patterns in clinically meaningful terms. Integrating spatial immune biomarkers with chronological age, biological frailty, comorbidity, and treatment exposure may improve patient selection and support more personalized cancer care.

Introduction

Age is one of the strongest determinants of cancer incidence, cancer mortality, treatment tolerance, and immune function. The tumor immune microenvironment is not static; it evolves with host ageing, malignant progression, therapy, infection history, metabolic status, and tissue-specific biology. Consequently, two tumors with similar histology and genomic alterations may display markedly different immune-cell distributions in younger and older patients. The location of immune cells is particularly important because physical proximity determines access to tumor antigens, exposure to suppressive cytokines, interaction with antigen-presenting cells, and the ability of effector lymphocytes to contact malignant cells.

Age-related immune remodeling is often described as immunosenescence, but this term encompasses several distinct processes. T-cell repertoire contraction, reduced thymic output, impaired clonal expansion, accumulation of highly differentiated or exhausted lymphocytes, altered innate immune signaling, and chronic low-grade inflammation occur alongside remodeling of fibroblasts, endothelial cells, extracellular matrix, and tissue-resident immune niches. These changes can generate tumors that are highly inflamed at the periphery but poorly infiltrated at the center, or tumors dominated by suppressive myeloid populations and regulatory lymphocytes. Understanding spatial organization therefore provides a bridge between basic ageing biology, pathology, and clinical decision-making.

Keywords

tumor immune microenvironment, ageing, immunosenescence, inflammaging, spatial transcriptomics, tumor-infiltrating lymphocytes, immune checkpoint inhibitors, myeloid-derived suppressor cells, cancer immunotherapy, multiplex imaging

Epidemiology / Disease Burden

Cancer incidence rises sharply with advancing age, reflecting cumulative genomic damage, altered tissue repair, prolonged exposure to carcinogens, and declining immune surveillance. Older adults account for a large and increasing proportion of cancer diagnoses worldwide. The clinical burden is amplified by multimorbidity, polypharmacy, functional decline, nutritional impairment, and reduced physiological reserve. These factors may affect both the composition of the tumor microenvironment and the capacity to receive intensive systemic treatment.

Age-related differences in tumor immune organization have been reported across melanoma, lung cancer, breast cancer, colorectal cancer, renal cell carcinoma, pancreatic cancer, and hematologic malignancies. However, associations are not uniform. Some studies identify reduced cytotoxic lymphocyte infiltration or impaired spatial proximity between CD8-positive T cells and tumor cells in older patients, whereas others report increased inflammatory myeloid signatures or similar checkpoint ligand expression across age groups. Differences in tumor type, stage, prior therapy, anatomic site, microbiome, tissue sampling, and analytical methodology contribute to these apparently conflicting findings. Chronological age alone is therefore an incomplete epidemiological marker. Biological age, frailty, sarcopenia, systemic inflammatory status, and lifetime immune exposure may better explain clinically relevant variation.

Pathophysiology

Ageing changes the cellular composition of the tumor microenvironment through several interacting mechanisms. Thymic involution reduces the generation of naive T cells and increases reliance on peripheral homeostatic proliferation. The resulting repertoire may contain fewer diverse tumor-reactive clones and a greater proportion of senescent, terminally differentiated, or exhausted cells. Older T cells can express inhibitory receptors such as programmed cell death protein 1, T-cell immunoglobulin and ITIM domain, lymphocyte activation gene 3, and other dysfunction-associated markers. Their reduced proliferative capacity and altered cytokine production may limit tumor penetration and durable antitumor responses.

Ageing also affects dendritic-cell maturation, antigen processing, and migration to draining lymph nodes. Impaired antigen presentation may reduce the priming of new tumor-specific clones. Natural killer cells frequently increase numerically with age but may undergo changes in receptor balance, cytotoxicity, and tissue distribution. B-cell composition, antibody quality, and tertiary lymphoid structure formation may also change, influencing local antigen presentation and immune coordination.

Myeloid remodeling is a central feature of the ageing tumor microenvironment. Senescent stromal and epithelial cells release inflammatory mediators, including interleukin-6, interleukin-1 family cytokines, tumor necrosis factor, chemokines, and matrix-modifying enzymes. This chronic inflammatory state can recruit monocytes, tumor-associated macrophages, and myeloid-derived suppressor cells. These populations may cluster around blood vessels, necrotic regions, invasive margins, or fibrotic bands, creating barriers to lymphocyte movement. Macrophage polarization is not binary, but ageing may favor metabolically adapted, immunosuppressive, and tissue-remodeling states that promote tumor growth and immune exclusion.

Fibroblasts and extracellular matrix components are equally important. Age-associated collagen cross-linking, increased matrix stiffness, altered hyaluronan content, and cancer-associated fibroblast activation can narrow intercellular spaces and impair T-cell migration. Transforming growth factor beta signaling may promote fibroblast-mediated exclusion while suppressing cytotoxic lymphocyte function. Abnormal tumor vasculature, endothelial adhesion defects, and increased perivascular suppression can prevent circulating effector cells from entering malignant compartments. Lymphatic remodeling may alter antigen drainage and the delivery of immune cells from regional lymph nodes.

These processes produce recognizable spatial phenotypes. In an immune-desert pattern, few immune cells are present within or around the tumor. In an immune-excluded pattern, lymphocytes accumulate at the invasive margin or in stromal regions but fail to enter tumor nests. In an inflamed pattern, cytotoxic lymphocytes and antigen-presenting cells are distributed near malignant cells and may form organized immune niches. Age-related stromal, vascular, and myeloid changes can shift tumors from an inflamed pattern toward exclusion or suppression, although selected older patients may retain robust inflammation and respond well to immunotherapy.

Risk Factors

Risk factors for unfavorable age-associated immune organization include advanced chronological age, frailty, obesity, physical inactivity, smoking, chronic infection, diabetes, renal or hepatic dysfunction, malnutrition, and persistent systemic inflammation. Prior cytotoxic chemotherapy, radiotherapy, corticosteroid exposure, targeted therapy, and prolonged hospitalization may further alter immune-cell trafficking and clonal diversity. Dysbiosis of the intestinal microbiome can affect systemic immune tone and treatment response, while antibiotic exposure may reduce microbial diversity and impair the efficacy of some immunotherapies.

Genetic and tumor-specific factors also modify spatial organization. High tumor mutational burden, mismatch repair deficiency, viral oncogenesis, and abundant neoantigens may support lymphocyte recruitment, but these signals can be neutralized by suppressive stroma or dysfunctional antigen presentation. Tumor location, metastatic site, hypoxia, necrosis, and oncogenic pathways involving beta-catenin, mitogen-activated protein kinase signaling, or transforming growth factor beta further influence immune-cell positioning. Risk assessment should therefore integrate host, treatment, tumor, and microenvironmental variables rather than relying on age as an isolated predictor.

Clinical Features

Spatial immune organization rarely produces distinctive symptoms by itself. Its clinical expression is usually inferred from tumor behavior, disease tempo, laboratory findings, pathological examination, and response to treatment. Immune-excluded tumors may exhibit progressive local invasion or metastatic spread despite the presence of substantial lymphocytes at the periphery. Immune-desert tumors may show limited inflammatory pathology and poor response to therapies that depend on pre-existing T-cell activation. Conversely, inflamed tumors may be associated with favorable prognostic features in some cancers, although excessive inflammation can also support angiogenesis, tissue destruction, and immune suppression.

Older patients with disorganized or suppressive immune niches may experience reduced benefit from immune checkpoint blockade, delayed responses, or a greater need for combination treatment. Nevertheless, age should not be used to deny immunotherapy. Some older adults have highly active tumor-reactive immune populations and can achieve durable responses. Clinical assessment should include performance status, frailty, nutritional state, comorbidities, organ function, medication review, and patient goals. These factors often predict treatment tolerance more accurately than age alone.

Diagnosis

Routine histopathology can estimate the density and distribution of tumor-infiltrating lymphocytes, but conventional staining provides limited information about cellular identity, functional state, and spatial relationships. Immunohistochemistry for CD3, CD8, CD4, regulatory T-cell markers, programmed cell death protein 1, programmed death ligand 1, macrophage markers, and dendritic-cell markers can provide clinically useful information when interpreted with tumor type and assay-specific standards.

Multiplex immunofluorescence and imaging mass cytometry permit simultaneous assessment of numerous markers while preserving tissue geography. Spatial transcriptomics can map gene-expression programs to tumor, stromal, vascular, and immune compartments. Digital pathology can quantify distances between immune cells and malignant cells, identify immune aggregates, assess invasive margins, and evaluate tertiary lymphoid structures. Single-cell sequencing adds information about clonal diversity and cellular states but may lose precise positional context when tissue is dissociated.

Clinically useful assessment should report not only the number of immune cells but also their localization, phenotype, clonality, and interaction with stromal barriers. Sampling error remains important because small biopsies may not represent heterogeneous tumors. Repeated sampling, radiographic correlation, and standardized computational pipelines are needed before many spatial biomarkers can be routinely incorporated into treatment guidelines. Blood-based markers of immune ageing, including lymphocyte subsets, inflammatory proteins, and T-cell receptor diversity, may complement tissue analysis but cannot substitute for direct spatial evaluation.

Treatment & Management

Management should be individualized according to tumor type, stage, molecular characteristics, treatment history, biological age, and functional reserve. Immune checkpoint inhibitors remain central for many advanced cancers, but their activity depends partly on the presence and functional competence of tumor-reactive lymphocytes. In immune-excluded tumors, combining checkpoint blockade with strategies that modify fibroblasts, transforming growth factor beta signaling, tumor vasculature, chemokine pathways, or myeloid suppression may improve lymphocyte access. In immune-desert tumors, vaccination, radiotherapy, oncolytic approaches, epigenetic therapy, or selected targeted agents may help generate or expose tumor antigens.

Myeloid-directed treatments are being investigated to reduce suppressive macrophage and myeloid-derived suppressor cell populations. Potential approaches include colony-stimulating factor 1 pathway inhibition, phosphoinositide 3-kinase gamma modulation, adenosine pathway blockade, and agents that improve antigen presentation. These strategies require careful attention to infection risk, marrow reserve, and inflammatory toxicity, particularly in older adults. Antiangiogenic therapy may normalize abnormal vessels and increase immune-cell entry, but dose selection and monitoring are essential in patients with cardiovascular or renal comorbidity.

Cellular therapies and cancer vaccines may be affected by age-related reductions in T-cell fitness and clonal diversity. Manufacturing strategies that select less differentiated T cells, optimize metabolic conditioning, or enhance persistence may partially address these limitations. Supportive management, including vaccination against preventable infections, nutritional optimization, exercise adapted to functional capacity, medication review, and early management of treatment-related immune toxicity, is an important component of care. Geriatric assessment should be integrated into treatment planning rather than used solely to exclude patients from trials or intensive therapy.

Recent Advances / Emerging Therapies

Spatial multi-omics is rapidly transforming investigation of age-related tumor immunity. New platforms combine RNA expression, protein markers, chromatin accessibility, receptor clonality, and tissue coordinates, allowing researchers to identify cellular neighborhoods associated with treatment response or resistance. Machine-learning models can quantify immune architecture and integrate spatial features with genomic and clinical variables. Such tools may eventually distinguish chronological ageing from reversible immune dysfunction caused by treatment, malnutrition, or systemic disease.

Emerging therapeutic concepts include senolytic agents, senomorphic drugs, metabolic reprogramming, microbiome modulation, and interventions that restore dendritic-cell function. Senescent cells may create a pro-inflammatory but immunosuppressive niche through their secretory phenotype; removing or modifying these cells could improve immune-cell organization, although clinical safety remains under investigation. Agents targeting cellular metabolism may enhance the persistence of exhausted T cells within nutrient-depleted tumors. Personalized vaccines and engineered T-cell products may be designed using spatially defined neoantigen niches and patient-specific receptor information.

Age-inclusive clinical trials are essential. Older adults are frequently underrepresented or categorized only by an upper age cutoff, limiting understanding of treatment efficacy and toxicity across biological ageing states. Future studies should prespecify analyses of frailty, immune composition, spatial architecture, organ function, and patient-reported outcomes. Longitudinal tissue and blood sampling may clarify whether therapy restores favorable immune organization or merely changes the abundance of selected markers.

Guideline Recommendations

Current oncology guidelines generally recommend treatment selection according to tumor histology, stage, molecular biomarkers, performance status, comorbidity, and validated predictive assays rather than chronological age alone. In practice, clinicians should follow approved indications for checkpoint inhibitors and other systemic therapies while incorporating geriatric assessment for older adults. Pathology reports should use validated methods for tumor-infiltrating lymphocytes and programmed death ligand 1 where these biomarkers are guideline-supported, recognizing that assay thresholds and interpretation differ by cancer type.

For patients considered for immunotherapy, clinicians should document baseline autoimmune disease, infection risk, organ function, concomitant immunosuppressive medication, vaccination status, and functional reserve. Management of immune-related adverse events should follow established multidisciplinary protocols, with prompt evaluation of new symptoms and appropriate corticosteroid or immunomodulatory treatment when indicated. Spatial biomarkers outside validated clinical assays should currently be regarded as investigational and should not replace established staging, molecular testing, or shared decision-making.

Guideline-concordant care should also include prevention of treatment interruption when possible, coordination with geriatrics, attention to nutrition and mobility, and explicit discussion of goals and expected benefit. Older age may increase the consequences of toxicity, but it does not reliably predict lack of response. Decisions should be based on an integrated estimate of benefit, risk, life expectancy, competing illness, and patient preference.

Conclusion

Age-related changes in tumor immune cell spatial organization arise from the combined effects of immunosenescence, inflammaging, stromal remodeling, vascular dysfunction, altered antigen presentation, metabolic stress, and treatment exposure. These processes determine whether immune cells reach malignant cells, remain trapped in peripheral stroma, or adopt suppressive phenotypes within tumor niches. Spatial analysis therefore offers a biologically informative complement to cell counts, checkpoint ligand expression, and genomic biomarkers.

For clinical practice, chronological age should not serve as a surrogate for immune competence or a standalone exclusion criterion for immunotherapy. Comprehensive assessment of frailty, comorbidity, tumor biology, immune architecture, and treatment goals is more appropriate. Continued development of standardized spatial assays, age-inclusive trials, and mechanism-based combination therapies may enable clinicians to convert unfavorable immune geography into a therapeutically accessible microenvironment. Integrating spatial tumor immunology with geriatric oncology has the potential to improve prediction, reduce toxicity, and deliver more precise cancer care across the ageing population.